Opdyta 100mg
Opdyta 100mg is prescription drug which is used under the supervision of doctorOpdyta 100mg injection belongs to human monoclonal antibody which stops the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Opdyta 100mg is an IgG4 kappa immunoglobulin which has a calculated molecular mass of 146 kDa. It is expressed in a recombinant Chinese Hamster Ovary (CHO) cell line.
Opdyta 100mg injection is also known as an immune checkpoint inhibitor. Sometimes these drugs are called targeted therapies because they target specific proteins (receptors) on the surface of cells.
INDICATION
Opdyta 100mg is indicated for the treatment of patients having :• Melanoma
• Non-Small Cell Lung Cancer
• Kidney (Renal Cell) Cancer
DOSAGE
Opdyta 100mg injection recommended dosage for unresectable or metastatic melanoma:As single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity
With ipilimumab:
The recommended dose of Opdyta is 1mg/kg administrated as an intravenous infusion over 30 minutes, followed by ipilimumab 3mg/kg given as IV over 90 minutes on the same day. Duration 3 weeks of max 4 doses, after completing combination Opdyta 100mg injection dose continue the single agent treatmentFor adjuvant treatment of melanoma:
As single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity for up to 1 yearOpdyta 100mg injection.For Non-small cell lung cancer:
Opdyta 100mgAs single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity.For small cell lung cancer :
Opdyta 100mg injection As single agent is either 240mg every 2 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity for up to 1 year.For renal cell carcinoma:
Opdyta 100mg As single agentDosage either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity.
With ipilimumab
Opdyta of 3mg/kg administrated as IV infusion over 30 minutes and followed by 1mg/kg administrated as IV infusion over 30minutes on the same day. Duration 3 weeks of max 4 doses, after completing combination dose continue the single agent treatment.
MECHANISM
Binding of these ligands to the PD-1 receptor occur on T cells, prohibits T cell multiplication and cytokine production. Opdyta 100mg injection Upregulation of the PD-1 ligands occurs in some tumor and signallingvia this pathway can provide to prohibition of active T-cell immune surveillance of tumor. Nivolumab belongs to human immunoglobulin G4 (IgG4) monoclonal antibody which binds to the PD-1 receptor and stops its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated prevention of the immune response,Opdyta 100mg containing the anti-tumor immune response, resulting in reduced tumor growth.ADME
Absorption:The time to peak plasma concentration is between 1-4 hours
Distribution:Volume of distribution is reported to be 8L
There is no information regarding the plasma protein bounding
Elimination: Half-life elimination of Opdyta is 26.7 days.
DRUG INTERACTION
No formal pharmacokinetic drug interaction studies Opdyta 100mg injectionPRECAUTION
Immune-mediated pneumonitis may appear to the patients, hence withhold for moderate and Opdyta 100mgpermanently discontinue for serious or life-threatening pneumonitis.Other clinically important and possible fatal immune-mediated side effects (eg, myocarditis, rhabdomyolysis, myositis, uveitis, iritis, pancreatitis) can appear after therapy discontinuation.
Severe infusion reactions resulted (rare, <1%); discontinue if severe or life-threatening; break or slow rate of infusion in patients with mild or moderate infusion reactions
Immune-mediated hepatitis seen in clinical trials; check for liver function changes;Opdyta 100mg injection withhold for limited and permanently stop for serious or life-threatening transaminase or total bilirubin elevation.
Opdyta may cause fetal harm; advise of possible risk to a foetus and use of effective contraception
STORAGE
Store at under refrigeration at 2℃ to 8℃.MISSED DOSE
If you missed a dose take it as soon as possible, if time reach for next dose, then skip missed dose and continue regular schedule.Opdyta 100mg injection Avoid taking two doses at a time. Avoid taking missed dose within 12hrs of the next dose.SIDE EFFECTS
Common side effects :Fatigue; Lymphocytopenia (Low White Blood Cells); Low Sodium; Shortness of breath; Musculoskeletal Pain; Decreased Appetite; Cough
Less common side effects :
Constipation; Increased serum creatinine; Colitis;Opdyta 100mg injection Low potassium; Low magnesium; High calcium; Vomiting; Weakness; Diarrhea; High potassium; Low calcium; Swelling; Fever; Rash; Abdominal pain; Increased serum AST; Thrombocytopenia; Increased serum alkaline phosphatase; Chest pain; Weight loss
Contact Details
Phone : +91-9987711567Email : applepharmaceutical@gmail.com
Email : info@myapplepharma.com
Comments
Post a Comment